Online inquiry

IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4563MR)

This product GTTS-WQ4563MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CXCR4 gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001008540.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7852
UniProt ID P61073
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ4563MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13163MR IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-04518600
GTTS-WQ5201MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CAT-8015
GTTS-WQ5355MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CD38-Attenukine
GTTS-WQ7360MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ4197MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BIIB019
GTTS-WQ5227MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CB 2679d
GTTS-WQ7380MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GA101
GTTS-WQ5912MR IVTScrip™ mRNA-Anti-IL31RA, CIM 331(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CIM 331
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW